TransCode Therapeutics, Inc. Form 8-K Summary
Business context and reporting period
TransCode Therapeutics, Inc. filed a Current Report on Form 8-K regarding Nasdaq continued-listing deficiencies. The reported event occurred on May 16, 2023; the filing was signed on May 18, 2023. The company’s common stock trades under the symbol RNAZ on the Nasdaq Capital Market.
Key financial metrics and liquidity
- Stockholders’ equity as reported in the company’s Form 10-Q for the quarter ended March 31, 2023: $(236,792).
- Nasdaq’s minimum stockholders’ equity requirement for continued listing: $2.5 million.
- The filing does not provide revenue, net income or loss, cash flow, cash balance, margins, debt, or liquidity runway metrics.
- The company did not meet the alternative Nasdaq continued-listing standards based on market value of listed securities of $35 million or net income from continuing operations of $500,000.
Material changes and listing deficiencies
- On May 16, 2023, Nasdaq notified the company that it was not compliant with Nasdaq Listing Rule 5550(b)(1) because stockholders’ equity was below the required $2.5 million.
- The deficiency notification had no immediate effect on the company’s Nasdaq listing, subject to compliance with other continued-listing requirements.
- The equity deficiency is separate from a previously disclosed minimum bid price deficiency under Nasdaq Listing Rule 5550(a)(2), relating to failure to maintain a $1.00 closing bid price for 30 consecutive business days.
Outlook, contingencies, and risks
- The company had until June 30, 2023 to submit a plan to regain compliance with the stockholders’ equity requirement.
- If Nasdaq accepted the compliance plan, Nasdaq could grant an extension of up to 180 calendar days from the notification date to regain compliance.
- The company stated that it intended to submit the plan by June 30, 2023, monitor stockholders’ equity, and consider available options to regain compliance.
- The separate minimum bid price deficiency had an initial compliance deadline of June 7, 2023. If unresolved, the company could request, but might not qualify for, an additional 180-day period.
- Qualification for that additional period would require satisfaction of other initial listing standards, including a $5.0 million stockholders’ equity requirement, which the company was also deficient in meeting.
- Failure to regain compliance with either requirement could result in delisting from the Nasdaq Capital Market.
- Forward-looking statements regarding the compliance plan, Nasdaq’s response, financial condition, and continued listing are subject to execution, regulatory, financial, and market risks.
Investor verification checklist
- Verify the company’s subsequent Nasdaq compliance plan, Nasdaq response, and any granted extension.
- Verify whether the company regained compliance with the $1.00 minimum bid price requirement by June 7, 2023.
- Review subsequent financial statements for changes in stockholders’ equity, cash, debt, financing activity, and liquidity.
- Check for any Nasdaq delisting notice, hearing, appeal, reverse stock split, capital raise, or other remediation action.
- Review later SEC filings for developments affecting the company’s ability to maintain its Nasdaq listing.